Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.
Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?
Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.
Can United Immunity revive macrophage cell therapy after Carisma’s reset?
Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.
Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system
Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.
Can non-viral gene therapies solve the safety problem holding back genetic medicine?
Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.
How CPTx is positioning targeted lipid nanoparticles at the center of CAR T innovation
Explore how CPTx’s targeted lipid nanoparticle platform could reshape CAR T therapy scalability and access. Read the full analysis now.
What Lilly’s Orna Therapeutics deal means for immune reset strategies
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone […]